Services
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) In Vivo Toxicology Study Services
Are you currently facing complex regulatory hurdles, unpredictable safety profiles, or the need for a highly relevant translational model for your next-generation therapeutic? Creative Biolabs' Non-Human Primate (NHP) In Vivo Toxicology Service helps you streamline clinical trial processes and obtain accurate safety data through a highly relevant translational model for next-generation therapeutics. This is achieved through our advanced understanding of NHP physiology, robust study design, and extensive resources.
Introduction of NHP In Vivo Toxicology Service
NHPs have long served as a cornerstone of preclinical safety and toxicology assessments. Due to their close genetic, physiological, and anatomical similarities to humans, NHPs are often the most relevant translational model available. They possess complex organ systems, immunological responses, and neurological structures that closely mirror those of humans, making them indispensable for evaluating the safety of novel drug candidates. This is particularly critical for biologics and advanced therapies that are highly human-specific and would not engage targets in other non-rodent species.
What Our Service Is
Our NHP In Vivo Toxicology service provides comprehensive, end-to-end solutions for preclinical safety evaluation. We specialize in designing and executing studies that provide the critical data required for regulatory submissions and risk assessment. The key applications including:
- Monoclonal Antibody (mAb) Development: NHP studies are essential for the safety testing of human-specific mAbs. They enable the identification of potential pharmacology-based hazards before human trials.
- Neurotoxicology: Our services are crucial for understanding the neurotoxic effects of compounds. This includes studies that model diseases like Parkinson's, using a model with a complex neural system analogous to humans.
Why Choose Us?
In the competitive biopharmaceutical landscape, every decision is a critical step towards success. The pain points of the industry—unpredictable safety profiles and development setbacks—are directly addressed by the value we create. By choosing Creative Biolabs, you gain access to a platform that reduces the risk of late-stage failures by providing highly predictive safety data from a relevant species. Our expertise helps you to make science-based decisions and streamline your path to the clinic, ensuring the safety of your therapeutic and the well-being of future patients.
Key Benefits of Our Service
Creative Biolabs' NHP In Vivo Toxicology Studies service offers a distinct advantage, grounded in our unique capabilities and unwavering commitment to quality. Our services are built to address the most pressing challenges in preclinical development.
- Unparalleled Response Speed: We offer exceptional study initiation timelines, allowing you to move from protocol finalization to in-life study in a fraction of the time compared to industry averages. This is enabled by our agile operational structure and readily available, high-quality NHP resources.
- Access to Extensive NHP Resources: We maintain one of the most comprehensive and well-managed NHP colonies, providing you with access to diverse species and a consistent supply for both your immediate and long-term project needs.
- Study Customization: Our team of experts works collaboratively with you to design bespoke study protocols that are scientifically rigorous and tailored to the unique attributes of your therapeutic.
- Comprehensive Reporting: We provide in-depth, high-quality data and analysis, including detailed final reports, raw data sets, and a comprehensive interpretation of findings to inform your next steps.
How Creative Biolabs' NHP Studies Can Assist Your Project?
Our end-to-end toxicology studies are designed to provide you with the actionable insights you need to confidently advance your drug candidate. The process is a seamless collaboration, beginning with a clear understanding of your objectives and culminating in a comprehensive data package.
01
Required Starting Materials
02
Protocol Design & Review
03
Animal Selection & Conditioning
04
Study Execution
05
In-Life Data Collection
06
Sample Analysis & Interpretation
07
Final Reporting
Key Deliverables
- Final Study Report
- Raw Data Files (digital format)
- Histopathology Slides and Reports
- Clinical Pathology & Biomarker Data
- Executive Summary with Key Findings
Capabilities & Partnerships
Service-Specific Data
- Annual Sample Size: Over 50,000 samples analyzed per year.
- Turnaround Time (TAT): Typical turnaround of 2 weeks for bioanalytical results.
- Study Pass Rate: 99%+ success rate in meeting study endpoints.
Our Valued Partners
Frequently Asked Questions
Q: Why are NHPs necessary for my toxicology studies? Can't I just use a different species?
A: NHPs are not always required, but they are often the most scientifically appropriate model, particularly for drugs that are highly specific to human targets. For many biologics and advanced therapies, non-primate species simply lack the relevant physiological or genetic similarities to predict human responses. Our expert team will work with you to determine if an NHP study is the most justified and valuable approach for your unique project.
Q: Can you help me with a specific, complex therapeutic modality like a gene or cell therapy?
A: Absolutely. Our team has extensive experience in designing and executing toxicology studies for advanced therapies. We understand the unique challenges associated with these modalities and have the expertise to develop customized protocols that address potential safety concerns, such as off-target effects or unintended systemic distribution, in a highly relevant model.
Q: What if the safety data from the NHP study is not what we expected?
A: The primary goal of a toxicology study is to provide an accurate safety profile of your compound. Even if the data reveals unexpected findings, it is invaluable information that allows you to make informed decisions about your program. Our toxicologists will provide a detailed analysis to help you understand the implications of the findings and determine the most appropriate next steps, whether that involves dose adjustments or protocol modifications.
Q: I am unsure if an NHP study is the right fit for my project. How can I find out more?
A: We understand that choosing the right preclinical model is a critical decision. The best way to begin is by having a direct conversation with our scientific team. We can review your project details, discuss the advantages of an NHP model for your specific therapeutic, and provide a clear recommendation based on your goals and the regulatory landscape.
Contact Us
Ready to take the next step in your drug development journey? Our team of specialists is here to provide the insights and support you need to confidently advance your therapeutic. We invite you to reach out to us to discuss your project in detail.